CStone Pharmaceuticals (HKSE:02616) Risk Assessment

View and export this data going back to 2019. Start your Free Trial

What is CStone Pharmaceuticals Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of CStone Pharmaceuticals is: No Data: Cannot be evaluated.

Competitive Comparison of CStone Pharmaceuticals's Risk Assessment

For the Biotechnology subindustry, CStone Pharmaceuticals's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CStone Pharmaceuticals's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CStone Pharmaceuticals's Risk Assessment distribution charts can be found below:

* The bar in red indicates where CStone Pharmaceuticals's Risk Assessment falls into.

CStone Pharmaceuticals (HKSE:02616) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

CStone Pharmaceuticals Risk Assessment Related Terms

Thank you for viewing the detailed overview of CStone Pharmaceuticals's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

CStone Pharmaceuticals (HKSE:02616) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CStone Pharmaceuticals (HKSE:02616) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

CSPHF:USA PH4:Germany

Address

218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Shanghai, CHN, 215123

Website

https://www.cstonepharma.com

CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.

Executives

Su Zhou Gong Ye Yuan Qu Zheng Ze Yuan Shi Chuang Ye Tou Zi Qi Ye You Xian He Huo	2101 Beneficial owner
Su Zhou Gong Ye Yuan Qu Zheng Ze Ji Ming Gu Quan Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Zheng Ze Jian Kang Chuang Ye Tou Zi Guan Li Zhong Xin You Xian He Huo	2501 Other
Su Zhou Gong Ye Yuan Qu Yuan He Yuan Dian Chuang Ye Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Guan Wei Hui	2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Jing Ji Fa Zhan You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Yuan He Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Fei Jianjiang	2201 Interest of corporation controlled by you
Wuxi Healthcare Ventures Ii, L.p.	2101 Beneficial owner
Wuxi Healthcare Management, Llc	2201 Interest of corporation controlled by you
Morgan Stanley	2201 Interest of corporation controlled by you
Gic Private Limited	2102 Investment manager
Jiang Frank Ningjun	2307 Founder of a discretionary trust who can infl
Graceful Beauty Limited	2101 Beneficial owner
Boyu Capital Holdings Ltd.	2201 Interest of corporation controlled by you

CStone Pharmaceuticals (HKSE:02616) Headlines

No Headlines